Nureca Ltd
Incorporated in 2016, Nureca Ltd is in the business of home healthcare and wellness products[1]
- Market Cap ₹ 285 Cr.
- Current Price ₹ 286
- High / Low ₹ 448 / 198
- Stock P/E
- Book Value ₹ 192
- Dividend Yield 0.00 %
- ROCE 0.33 %
- ROE -0.36 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 2.89% over past five years.
- Company has a low return on equity of -1.93% over last 3 years.
- Earnings include an other income of Rs.12.5 Cr.
- Company's cost of borrowing seems high
- Promoter holding has decreased over last 3 years: -5.70%
- Working capital days have increased from 241 days to 408 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 5m | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 1 | 99 | 213 | 256 | 112 | 95 | 115 | |
| 0 | 1 | 1 | 90 | 152 | 200 | 127 | 106 | 124 | |
| Operating Profit | 0 | 0 | 0 | 10 | 62 | 56 | -15 | -11 | -10 |
| OPM % | 0% | 3% | 4% | 10% | 29% | 22% | -14% | -12% | -8% |
| 0 | 0 | 0 | 0 | 3 | 8 | 7 | 11 | 13 | |
| Interest | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
| Profit before tax | 0 | 0 | 0 | 9 | 62 | 61 | -11 | -3 | -0 |
| Tax % | 50% | 33% | 26% | 26% | 26% | -23% | -25% | 46% | |
| 0 | 0 | 0 | 6 | 47 | 45 | -8 | -2 | -1 | |
| EPS in Rs | 0.00 | 20.00 | 20.00 | 6,410.00 | 46.53 | 45.31 | -8.42 | -2.44 | -0.67 |
| Dividend Payout % | 0% | 0% | 0% | 4% | 7% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -23% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 72% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -34% |
| 1 Year: | 3% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | -2% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 0 | 0 | 0 | 15 | 153 | 194 | 185 | 183 | 182 |
| 0 | 0 | 0 | 10 | 4 | 4 | 3 | 2 | 4 | |
| 0 | 0 | 1 | 9 | 19 | 11 | 8 | 9 | 10 | |
| Total Liabilities | 0 | 0 | 1 | 34 | 186 | 220 | 207 | 204 | 206 |
| 0 | 0 | 0 | 1 | 3 | 10 | 8 | 6 | 8 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 1 | 34 | 62 | 97 | 4 |
| 0 | 0 | 1 | 33 | 181 | 175 | 136 | 101 | 194 | |
| Total Assets | 0 | 0 | 1 | 34 | 186 | 220 | 207 | 204 | 206 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| -0 | -8 | 35 | 2 | 12 | -3 | -19 | |||
| 0 | -0 | -110 | -3 | -18 | 18 | 9 | |||
| 0 | 8 | 92 | -7 | -2 | -1 | -1 | |||
| Net Cash Flow | 0 | -0 | 17 | -9 | -8 | 14 | -11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365 | 87 | 65 | 47 | 0 | 4 | 14 | 7 | 14 |
| Inventory Days | 0 | 101 | 590 | 93 | 135 | 174 | 154 | 156 | 163 |
| Days Payable | 233 | 849 | 33 | 32 | 13 | 23 | 27 | 26 | |
| Cash Conversion Cycle | 365 | -45 | -195 | 107 | 103 | 165 | 145 | 136 | 151 |
| Working Capital Days | 182 | -12 | -45 | 85 | 62 | 110 | 152 | 163 | 408 |
| ROCE % | 100% | 75% | 76% | 67% | 33% | -5% | -1% | 0% |
Documents
Announcements
-
Closure of Trading Window
28 Jun - Trading window closed from July 1, 2025, until 48 hours post Q1 financial results announcement.
- Closure of Trading Window 28 Jun
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
17 Jun - Nureca's AGM approved FY25 financials, director reappointments, auditor appointments, CEO remuneration, and merger scheme.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
17 Jun - AGM approved FY25 financials, director reappointments, auditors, CEO remuneration, and merger scheme.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
16 Jun - Nureca's AGM approved FY25 financials, director reappointments, CEO pay, and merger scheme with Nureca Technologies Pvt Ltd.
Business Overview:[1]
Nureca Limited operates as a digital-first healthcare company with a diverse and innovative portfolio catering to the home healthcare and wellness segment. The company is recognized for its flagship brand Dr Trust and focuses on delivering high-quality, accessible, and technology-driven solutions to customers.